Moderate hypofractionated boost to the prostate with pelvic RT (external beam radiotherapy) for Prostate Cancer
Study Summary
This trial is testing a new cancer treatment for 100 patients with high-risk or node-positive prostate cancer. The treatment is a combination of radiotherapy and androgen deprivation therapy.
- Prostate Cancer
Treatment Effectiveness
Study Objectives
1 Primary · 7 Secondary · Reporting Duration: Baseline to 5-year follow-up
Trial Safety
Trial Design
1 Treatment Group
Moderate Hypofracitonated Boost to the Prostate with Pelvic Radiation Therapy
1 of 1
Experimental Treatment
100 Total Participants · 1 Treatment Group
Primary Treatment: Moderate hypofractionated boost to the prostate with pelvic RT (external beam radiotherapy) · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · Male Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How many individuals are currently engaged in this medical experiment?
"Indeed, clinicaltrials.gov data shows that this investigation is actively recruiting patients after its initial posting on July 18th 2022 and latest update on the same day. The research requires 100 participants to be recruited from 1 site." - Anonymous Online Contributor
Is enrollment available in this clinical trial at the present time?
"According to the records on clinicaltrials.gov, this trial is open for enrolment. The study was initially made available on July 18th 2022 and has since been updated as of that same date." - Anonymous Online Contributor